Dr. Dr. Juan Carlos Munoz?

Dr. Dr. Juan Carlos Munoz

Gastroenterologist | Gastroenterology

4800 Belfort Rd Jacksonville FL, 32256 Show map

About
Contacts & Locations

About

Dr. Juan Munoz is a gastroenterologist practicing in Jacksonville, FL. Dr. Munoz specializes in the digestive system and its diseases that affect the gastrointestinal tract, which include organs from the mouth to the anus as well as liver disorders. Gastroenterology includes conditions such as hepatitis, peptic ulcer disease, colitis, nutritional problems and irritable bowel syndrome. Dr. Munoz performs colonoscopy and endoscopy procedures and provides accurate and thorough care for patients suffering from digestive issues.

Education and Training

Universidad Complutense MD 1992

Xochicalco School of Medicine MD 1986

Board Certification

American Board of Internal Medicine

Gastroenterology (Internal Medicine)

Provider Details

Male English, Spanish

Dr. Dr. Juan Carlos Munoz

Dr. Dr. Juan Carlos Munoz's Expert Contributions

My Answers

Why do I get full off of very little food?
Here is the response to the question: Thank you for your question. As compared to how you should feel when eating normally, early satiety happens when a person feels full after taking a few bites of meal sizes. Let me remind you very briefly about how the digestion process works: so after chewing, the food bolus is swallowed and it travels through the esophagus into the stomach. In the stomach, the food has to be triturated to smaller sized; peristalsis (stomach contractions) and gastric acid (gastric juice) participate in this process. Once the food bolus reaches a small size, it progresses from the stomach through the pylorus opening into the small bowel. Anything that interferes or impairs this normal stomach process can lead to feeling early satiety. It becomes a more serious problem when other symptoms accompany the process, such as nausea with or without vomiting, food regurgitation, heartburn, bloating, abdominal pain, dark/black stool, and loss of appetite. Early satiety can be seen in patients with diabetes mellitus, which is the most common cause of gastric emptying delay, also known as a “gastro paresis” or “lazy stomach.” Other problems in which early satiety is sometimes the first manifestation includes anorexia nervosa, bulimia, medication side effect, gastritis, gastric ulceration, gastric/intestinal surgeries. In elderly patients, we also have to rule out Parkinson’s disease, multiple sclerosis, malignancy, which cause gastric outlet obstruction. Therefore, if early satiety is interfering with your normal life, contact your pediatrician for an early evaluation that also includes a physical exam and simple blood work. READ MORE

Areas of expertise and specialization

Acid reflux disease (Gastroesophageal reflux/ GERD)ConstipationIrritable Bowel Syndrome (IBS)Advanced endoscopy procedures, including ERCPSingle balloon enteroscopyDouble balloon enteroscopyDilationsSEMS placementPEG placementHemorrhoid banding

Faculty Titles & Positions

Director of the Endoscopy Units UF & Shands Hospital 2011 - 2015
Associate Professor, Division of Gastroenterology, University of Florida 2011 - 2015
Assistant Program Director, Division of Gastroenterology University of Florida 2010 - 2011
Clinical Assistant Professor, Division of Gastroenterology University of Florida 2004 - 2010

Awards

Exemplary Teachers Award 2015 University of Florida College of Medicine
Exemplary Teachers Award 2012 University of Florida College of Medicine
Exemplary Teachers Award 2010 University of Florida College of Medicine
Predictive Factors of In-Hospital Mortality in Acute Esophageal Variceal Bleeding 2004 United Health Organization; Presented at Digestive Disease Week

Professional Memberships

American Society for Gastrointestinal Endoscope
Florida Gastroenterology Association
Florida Medical Association
American Gastroenterology Association
American College of Physicians

Charities and Philanthropic Endeavors

St. Jude Medical Hospital - donations to kids in need

Internships

St. Lukes Hospital

Fellowships

University of Florida College of Medicine

Areas of research

Research Training

1/25/2021 NIDA Good Clinical Practice
3/1/2018 CITI Good Clinical Practice Course

5/4/2016 TransCelerate ICH GCP

Research Experience

Principal Investigator:

2021-Present Arena APD334-202, Crohn’s Disease
2017 Celgene GED-0301-CD-002, Crohn’s Disease
2011 Actelion Pharma Ltd., CDI
2009-2011 Takeda Pharma, COPD pts. w. GERD
2009-2010 The Use of Self-Expanding Metal Stents During Acute

Colonic Obstruction Due to Intrinsic or Extrinsic Malignancies

2009-2010 The Use of Polyflex Stents in Acute Esophageal Disease
2008-2010 Identification of Esophageal Stem and Progenitor Cell Markers in

African Americans and Non-Hispanic Whites

2008-2010 Expression of Esophageal Tight Junction Proteins and RNA in

African Americans and non-Hispanic Whites

2008-2009 Nutritional Status as a Predictor of Poorer Outcomes in

Colorectal Cancer Amongst African Americans

2008 Unusual Object Removed from the Upper Gastrointestinal Tract:

Case Series and Literature

2007-2009 Are ACE inhibitors Protective Against Liver Fibrosis in Patients

with Hepatitis C

2007-2009 Novartis, OIC in patients with Chronic non-cancer pain
2007 Association of Diabetes Mellitus with Colorectal Cancer, Polyps,

Inflammatory Bowel disease, and Other colon Pathology

2005-2007 Genzyme Corporation GD3-170-301, C-Diff associated with

Diarrhea

2005-2007 Association of Diabetes Mellitus and Other Factors with

Subsequent Colorectal Cancer Risk

2003 Characterization of Upper Gastro-intestinal Bleeding in Patients

with Cirrhosis Induced by Alcohol Alone, Hepatitis C with or

without Alcohol Consumption

Sub-Investigator:

2022-Present GIE PR2053 PATENT-B, Bowel Stricture
2022-Present GIE PR2052 PATENT-E, Esophageal Stricture
2022-Present Hepion HEPA-CRV431-207, NASH
2022-Present Gilead GS-US-454-6075, NASH
2022-Present Kowa K-001-201, NASH
2022-Present Salix RNLC3131, CIRRHOSIS
2022-Present Axcella Health AXA1125-101, NASH
2022-Present Celgene CC-93538-EE-002, Eosinophilic Esophagitis
2021-Present Olympus OCA 2019-GI-03, Colorectal Polyp Clinical Decision

Support Device

2021-Present Phathom NERD-301, Non-Erosive Gastroesophageal Reflux

Disease

2021-2022 Allakos AK002-023, Eosinophilic Gastritis and/or Eosinophilic

Duodenitis

2021-2022 Alnylam ALN-HSD-001, NASH
2021-Present Genfit GFT505B-319-1, Primary Biliary Cholangitis
2021-Present Allakos AK002-021, Eosinophilic Duodenitis
2021-Present Celgene CC-93538-EE-001, Eosinophilic Esophagitis
2021-2022 Phathom NERD-201, Non-Erosive Gastroesophageal Reflux

Disease

2020-2022 Metacrine MET642-201, NASH
2020-Present Allakos AK002-016X EXT to Eosinophilic Gastritis and/or

Eosinophilic Gastroenteritis

2020-Present Neurogastrx NG101-201, Gastroparesis
2020-2021 Lucid EG-CL-102, Adenocarcinoma
2020-2021 Lucid EG-CL-101, Barrett’s Esophagus
2020-2021 Shire SHP647-303, Severe Ulcerative Colitis
2020-Present Enanta EDP305-102, NASH
2020-Present Allakos AK002-014, Eosinophilic Esophagitis
2020-2022 Allakos AK002-016, Eosinophilic Gastritis and/or Eosinophilic

Gastroenteritis

2020 Allakos AK002-019, Eosinophilic Gastrointestinal Diseases
2020-2021 SERES-201, Ulcerative Colitis
2020-2021 Phathom HP-301, H. Pylori
2020-Present Phathom EE-301, Erosive Esophagitis
2019-2021 Gilead GS-US-365-4237 FALCON, Ulcerative Colitis
2019-2021 Braintree BLI4900-302, Colon Prep
2019-Present Adare SP-1011-003, Eosinophilic Esophagitis
2019-Present AbbVie M14-533, Ulcerative Colitis
2019-Present AbbVie M14-675, Ulcerative Colitis
2019-Present AbbVie M14-234, Ulcerative Colitis
2018-Present AbbVie M14-430, Crohn’s Disease
2018-Present AbbVie M14-431, Crohn’s Disease
2018-2021 Finch CP101-CDI-E02 PRISM Ext, C-Difficile
2018-2022 AbbVie M14-433, Crohn’s Disease
2018-2019 Enanta EDP305-301, NASH
2017-2020 Shire SHP647-302, Ulcerative Colitis
2017-2021 SERES 012, Recurrent C-Difficile
2017-2022 SERES 013, Recurrent C-Difficile
2017-2022 KC Specialty NI03-001, Chronic Pancreatitis
2017-2020 Medtronic COVSBCC0549 “BLINK”
2017-2019 Pfizer C1171002, NASH
2017-Present Finch/Crestovo CDI-001, C-Difficile
2016-2019 Novartis CLJN452A2202, Liver Disease
2011 Solvay Pharmaceuticals A Randomized, Double-Blind,

Double-Dummy, Efficacy, Safety and Tolerability Study of

Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive

Parkinson's Subjects Receiving Optimized Treatments with

Parkinson Medicinal Products, who Continue to Experience

Persistent Motor Fluctuations

2011 Centocor Ortho Biotech Inc., Prospective, Multicenter,

Randomized, Double-Blind, Placebo-Controlled Trial Comparing

REMICADE (infliximab) and Placebo in the Prevention of

Recurrence in Crohn’s Disease Patients Undergoing Surgical

Resection Who Are at an Increased Risk of Recurrence

2010-2012 Schering-Plough Research Institute P06086, Chronic HCV

Management of anemia.

2009-2012 Millennium C13008, Ulcerative Colitis and Crohn’s

2009-2010 Millennium C13007, Crohn’s
2009-2012 Millennium C13006, Ulcerative Colitis
2009-2011 Centecor C0524T18, Ulcerative Colitis
2009-2011 Centecor A Phase 2/3 Multicenter, Randomized,

Placebo-controlled, Double-blind Study to Evaluate the Safety

and Efficacy of Golimumab Induction Therapy, Administered

Intravenously, in Subjects with Moderately to Severely Active

Ulcerative Colitis

2009-2011 Pfizer Inc., FITNESS (Filibuvir in Treatment Naive HCV

Genotype 1 Subjects) A Phase 2, Randomized, Double-Blind,

Placebo-Controlled Study To Evaluate The Safety And Efficacy

Of Filibuvir Plus Pegylated Interferon Alfa-2a And Ribavirin In

Treatment Naive, HCV Genotype 1 Infected Subjects

2009 Alba Therapeutics A Phase Ilb, Randomized, Double-Blind,

Placebo Controlled Study for the Treatment of Active Celiac

Disease with AT-1001

2009-2010 Centocor, Inc. A Phase 2b, Multicenter, Randomized,

Double-blind, Placebo-controlled, Parallel-group Study to

Evaluate the Efficacy and Safety of Ustekinumab Therapy in

Subjects with Moderately to Severely Active Crohn's Disease

Previously Treated with TNF Antagonist Therapy

2009-2010 Ambient Music Nature Therapy as an Adjunct to Colonoscopy
2009-2010 GSK Randomised, placebo-controlled, multi-centre study to

assess the efficacy and safety of eltrombopag in

thrombocytopenic subjects with hepatitis C virus (HCV)

infection who are otherwise eligible to initiate antiviral therapy

(peginterferon alfa-2b plus ribavirin) ENABLE 2 (Eltrombopag to

INitiate and Maintain Interferon Antiviral Treatment to Benefit

Subjects with Hepatitis C Related Liver Disease)

2008-2009 Sanofi-Aventis Inc. EFC10143, Non-Diabetic NASH
2008-2009 Sanofi-Aventis Inc. EFC10144, T2DM NASH
2008-2010 Schering-Plough Research Institute A Phase 3, Safety and

Efficacy Study of Boceprevir in Previously Untreated Subjects

With Chronic Hepatitis C Genotype

2008-2009 AGI Therapeutics Research Ltd. AG1003-003, IBS-D
2008-2009 Procter & Gamble A Multi-center, Investigator-blinded,

Randomized, 12-month, Parallel-group, Non-inferiority Study to

Compare the Efficacy of 1.6 to 2.4g Asacol® Therapy QD Versus

Divided Dose (BID) in the Maintenance of Remission of

Ulcerative Colitis

2008-2009 Pfizer, Inc. A randomized, double-blind, placebo-controlled,

parallel group, multi-center study to investigate the safety and

efficacy of cp-690,550 in subjects with moderate to severe

Crohn’s disease.

2008-2009 Hoffmann La-Roche, Inc. NV18210 Randomized, Multicenter,

Double-Blinded, Phase IV Study Evaluating the Efficacy (as

Measured by Sustained Virological Response) and Safety of 360

mg Induction Dosing of Pegasysâ in Combination with Higher

Copegusâ Doses in Treatment-naïve Patients with Chronic

Hepatitis C Genotype 1 Virus Infection of High Viral Titer and

Baseline Body Weight Greater than or Equal to 85 kg

2007-2009 Human Genome Sciences, Inc. A Phase 3, Randomized,

Multi-Center Study to Evaluate the Efficacy and Safety of

Albumin Interferon Alfa-2b (alb-IFN) in Combination with

Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS® or

PEG-IFNα2a) in Combination with Ribavirin in Interferon Alfa

Naïve Subjects with Chronic Hepatitis C Genotype 2 or 3

2007-2009 Human Genome Sciences, Inc. A Phase 3, Randomized,

Multi-Center Study to Evaluate the Efficacy and Safety of

Albumin Interferon Alfa-2b (alb-IFN) in Combination with

Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or

PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa

Naive Subjects with Chronic Hepatitis C Genotype

2007-2009 Altus Pharmaceuticals An Open-Label Clinical Study Evaluating

the Long Term Safety of ALTU-135 in the Treatment of Patients

with Exocrine Pancreatic Insufficiency due to Chronic

Pancreatitis or Pancreatectomy

2007-2008 AGI Therapeutics Research Ltd. AGI003-007, IBS-D
2006 (Mis) Use of Acid Suppression Therapy in Hospitalized Patients

On General Medicine Service - Going Beyond the Indications

2005-2009 Hoffmann-La Roche Inc., An extension protocol to evaluate the

long-term effects of treatment with peginterferon alfa-2a

(PEG-IFN)- or interferon (IFN)- based therapies for patients with

chronic hepatitis C

Dr. Dr. Juan Carlos Munoz's Practice location

Borland Groover Clinic

4800 Belfort Rd -
Jacksonville, FL 32256

Get Direction

Mon:09:00 AM - 05:00 PM
Tue:09:00 AM - 05:00 PM
Wed:09:00 AM - 05:00 PM
Thu:09:00 AM - 05:00 PM
Fri:09:00 AM - 05:00 PM
Sat:Closed
Sun:Closed

Dr. Dr. Juan Carlos Munoz's reviews

(0)

Write Review

Media Releases

Get to know Gastroenterologist Dr. Juan Carlos Munoz, who serves patients in Jacksonville, Florida.

A fellowship-trained gastroenterologist, Dr. Munoz provides excellence in digestive care at Borland Groover, practicing out of their Southside office in Jacksonville, Florida.

He has special interest and expertise in the treatment and care of the following digestive health concerns: acid reflux disease (gastroesophageal reflux / GERD), constipation, hepatitis c, irritable bowel syndrome (IBS), ulcerative colitis and others. He also provides advanced endoscopy procedures, esophageal and hemorrhoidal banding.

Back in 1991, Dr. Munoz graduated with his medical degree from the Faculty of Medicine of the Complutense University of Madrid in Spain. He then relocated to the United States, performing his internship in internal medicine at St. Luke’s Hospital in 1999. He also completed his residency in internal medicine and fellowship in gastroenterology at the University of Florida College of Medicine in 2001 and 2004, respectively.

Subsequent to his education, the doctor attained board certification in gastroenterology through the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

With over 30 years of experience, Dr. Munoz is affiliated with Baptist Medical Center Jacksonville, UF Health Jacksonville, and Ascension St. Vincent’s Southside Hospital.

Gastroenterology is the branch of medicine focused on the digestive system and its disorders. A gastroenterologist is a physician who has extensive training in the diagnosis and treatment of disorders related to the esophagus, stomach, small intestines, colon, liver, pancreas, and biliary system.

On a more personal note, Dr. Munoz speaks both English and Spanish.